Reported results
- Total worldwide sales were $18.1 billion.
- GAAP EPS was $2.04 and non-GAAP EPS was $2.49.
- KEYTRUDA/KEYTRUDA QLEX sales were $8.6 billion.
- WINREVAIR sales were $694 million.
- Animal Health sales were $1.7 billion.
- GAAP and non-GAAP EPS include a one-time charge of $0.12 per share related to a global license agreement with SciBrunch.
Guidance
- Full-year 2026 worldwide sales are expected to be between $66.8 billion and $67.3 billion.
- Full-year 2026 non-GAAP EPS is expected to be between $2.77 and $2.82.
- Full-year 2026 non-GAAP effective income tax rate is expected to be between 32.0% and 33.0%.
- Full-year 2026 non-GAAP operating expenses are expected to be between $42.4 billion and $42.9 billion.
Notes
The third quarter 2026 results include a one-time charge of $0.12 per share related to a global license agreement with SciBrunch. The 2026 full-year outlook includes one-time charges of $9.0 billion ($3.62 per share) for the acquisition of Cidara, $5.7 billion ($2.31 per share) for the acquisition of Terns, and $400 million ($0.12 per share) related to the global license agreement with SciBrunch.
Price and volatility reaction
The stock moved +3.8% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -2.9 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 140.93 | 2026-10-28 |
| Close after release | 146.33 | 2026-10-29 |
| Realised move | +3.8% | close to close |
| 30d ATM IV change | -2.9 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
